Orchid Pharma Limited · NSE:ORCHPHARMA

Orchid Pharma — Investor Presentation (December 2021)

13 slides from Orchid Pharma's investor presentation, Dec 23, 2021

  1. Slide 1: Orchid Pharma Regulation 30 disclosure letter

    OrchidPharma? * ( Formerly known as Orchid Chemicals & Pharmaceuticals Limited ) Corp. Off.: Orchid Pharma Ltd., ‘Orchid Towers’ 313, Valluvarkottam High Road, Nungambakkam, Chennai - 600 034. india. CIN: L24222TN1992PLC022994 December 23, 2021 National Stock Exchange of India Ltd BSE Limited Listin

  2. Slide 2: ice)

    355 ice) = © 1a as x — QW ho O — A Dhanuka Group Company —

  3. Slide 3: Background and Pedigree

    alii OrchidPharma¥ BACKGROUND AND PEDIGREE -©@@ee- DHANUKA AGRITECH LTD DHANUKA LABORATORIES LTD. ¢ Flagship of the Group founded in 1980. EN ¢ Pharmaceutical Arm started in 1998. £e ¢ Listed on Stock Exchanges for 35 years with a Market ¢ Leader in Cephalosporin Antibiotics in Emerging markets. Cap

  4. Slide 4: Merger Rationale

    OrchidPharmay MERGER RATIONALE -0@ @e- Planned during Resolution Plan haXod Management Economies of Focus on Scale / Single Entity Elimination of Operational Conflict of | Synergies Interest / Streamlined group Structure

  5. Slide 5: SWOT of Orchid and Dhanuka Laboratories

    arate: SOE EIEE eon OrchidPharma¥ ORCHID DHANUKA LABORATORIES Strengths 1. Regulatory Approvals — US / EU / Strengths Japan / LATAM 1. Cost Efficient Management 2. Large Capacity 2. strong R&D ses 3. Widest Range 3. Execution Capabilities Threats S Weaknesses S 1. Financial Stress |. High Cost threa

  6. Slide 6: Merged Entity Overview

    OrchidPharma? MERGED ENTITIY OVERVIEW DHANUKA LABS - PIONEER IN CEPHALOSPORIN ANTIBIOTICS Started in 1998, R&D Focused Dhanuka Laboratories. Acquired Orchid through CIRP Process on Ist April 2020 ABOUT DHANUKA LABORATORIES Started with Cephalosporins. Now both Ceph and NPNC Portfolio of Products \—

  7. Slide 7: Widest Range of Cephalosporins

    OrchidPharma? — A Dhanuka Group Company — WIDEST RANGE OF CEPHALOSPORINS GENERATION 4 ORAL ORAL ¢ Cefadroxil Cefprozil a > ¢ Cefalexin STERILE * Cefradine Cefepime STERILE Cefpirome STERILE STERILE Ceftobiprole Cefoxitin Cefquinome ¢ Cefalonium Ceforanide Cefiderocol ¢ Cefalothin Ceftolozane Cefotia

  8. Slide 8: NPNC Products

    OrchidPharma¥ — A Dhanuka Group Company — NPNC PRODUCTS Montelukast & Sitagliotin fa ¢ Citicoline ¢« Lacosamide ¢ Telmisartan ¢ Briveracetam ¢ Levetiracetam ¢ Molnupiravir ¢ Vildagliptin

  9. Slide 9: Merged Capacities (MTPA)

    OrchidPharma¥ — A Dhanuka Grou MERGED CAPACITIES (MTPA) Orchid Dhanuka Labs Oral m Sterile m@ Ceph-Oral mi NPNC Merged Entity mCeph Oral mCeph Sterile mNPNC

  10. Slide 10: Revenue Dhanuka Labs (Cr)

    OrchidPharma? ae REVENUE DHANUKA LABS (Cr) "© @@e@e- 450 on 0 6% 381.5 -2% 350 317.5 296.6 a: 300 250 200 150 100 1 0 35% 84.9 50 6.5 0 DLL-Ceph DLL-NPNC TOTAL m17-18 © 20-21

  11. Slide 11: EBITDA Dhanuka Labs (Cr)

    OrchidPharma¥ — A Dhanuka Group Comp EBITDA DHANUKA LABS (Cr) 35.0 30.0 29% 25.0 20.0 15.0 10.0 5.0 m17-18 = 20-21

  12. Slide 12: Merged Entity (Cr)

    OrchidPha OrchidPharma¥ MERGED ENTITY (Cr) 2020-21 900.0 832.3 800.0 700.0 600.0 500.0 400.0 300.0 200.0 95.9 100.0 Revenue =v M Orchid © DLL

  13. Slide 13: <4 oN

    <4 oN

Orchid Pharma — Investor Presentation (December 2021) on 6ix